A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.

Inclusion Criteria:

1. Has completed and signed an Informed Consent Form (ICF) prior to any study-relatedprocedures.

2. Able to understand and comply with study requirements.

3. Male or female aged 18 to 75 years, inclusive.

4. Clinical diagnosis of non-segmental vitiligo where the total affected BSA does notexceed 10%.

5. F-VASI score of ≥0.5 and ≤3.0.

6. T-VASI score of ≥3.0 and ≤10.0.

7. Agree to discontinue all agents used to treat vitiligo from Screening through thestudy completion. Over-the-counter preparations deemed acceptable by theinvestigator are permitted.

8. If receiving concomitant medication for any reason other than vitiligo, must be on astable regimen at Screening, and anticipating staying on a stable regimen throughthe study completion.

9. Female participants must:

• Be of non-childbearing potential (i.e., surgically sterilized [hysterectomy,bilateral salpingectomy, bilateral oophorectomy, tubal ligation/occlusion atleast 6 weeks before the Screening]) or postmenopausal (where postmenopausal isdefined as no menses for 12 months without an alternative medical cause) OR

• If of childbearing potential, must agree not to donate ova, not to attempt tobecome pregnant and, if engaging in sexual intercourse with a male partner,must agree to use an acceptable method of contraception from signing the ICFuntil at least 1 month after the last dose of IMP. An acceptable method ofcontraception includes one of the following:

1. Hormonal contraception (for at least 3 months prior to Screening) incombination with a barrier method.

2. Intrauterine device (placement at least 3 months prior to Screening).

3. Diaphragm with spermicide.

4. Cervical cap with spermicide.

5. Condoms with spermicide.

6. Vasectomized partner (6 months minimum since vasectomy).

7. Male participants, if not biologically or surgically sterilized, must agree not todonate sperm and, if engaging in sexual intercourse, must agree to use a condom fromsigning the ICF until at least 1 month after the last dose of study drug. Ifengaging with a female partner who could become pregnant, the female partner mustadditionally use an acceptable method of contraception for this same period.

Exclusion Criteria:

1. Clinical diagnosis of other forms of vitiligo (e.g., segmental) or other hypo- orde-pigmentation skin diseases (e.g., piebaldism, leukoderma, Vogt-Koyanagi-Haradadisease, malignancy induced hypopigmentation, etc.).

2. Concomitant dermatologic conditions or other medical condition(s) which may, in theopinion of the investigator, interfere with IMP application or study assessments.

3. History of melanocyte transplantation procedure or depigmentation treatment [e.g.Monobenzyl ether of hydroquinone (Monobenzone)].

4. Visible test site skin injury, damage, or observations in or around the applicationsite which, in the opinion of the investigator, will interfere with studyassessments or increase participation risk.

5. Dyed hair in the treatment area that could interfere with any clinical assessments.

6. Significant facial hair or are unable to maintain very short cropped facial hair (<5mm) during course of the study.

7. Leukotrichia in >33% of vitiligo lesional surface of the face or the body.

8. History or presence of any clinically significant condition(s) which, in the opinionof the investigator, could interfere with the course of the study or expose theparticipant to undue risk by participating in this study, including, but not limitedto: metabolic, allergic, cardiovascular, pulmonary, hepatic, renal, hematologic (including bleeding disorders), gastrointestinal (including peptic ulcer disease,gastritis or bleeding diathesis, excluding appendectomy or hernia repair),endocrine, immunologic, dermatologic, muscular, neurological, psychiatric,neoplastic, or other disease(s).

9. Major surgery within 3 months of randomization or with planned major surgery duringtrial.

10. Current or recent history (<30 days before Screening and/or <45 days beforerandomization) of a clinically meaningful bacterial, fungal, parasitic, ormycobacterial infection.

11. Any known or suspected premalignant or malignant disease within 5 years prior toScreening (excluding successfully treated basal or squamous cell carcinomas, actinickeratoses, melanoma in situ, cervical dysplasias, cervical cancer).

12. Systemic biologic or immune-modulating treatment within 12 weeks prior to Screeningand through study completion or topical treatment in the vitiligo areas within 2weeks prior to Screening and through study completion.

13. Received any investigational therapy, device or procedure within 30 days or 5half-lives (whichever is longer) prior to Screening. Investigational biologicsshould be discussed with the sponsor to determine if a longer period ofdiscontinuation is required.

14. Relevant (in the investigator opinion) ultraviolet light exposure includingphototherapy within 8 weeks prior to Screening.

15. Use of any other prior and concomitant therapy not listed above that, in the opinionof the investigator, may interfere with the evaluation of study outcomes, includingdrugs that cause photosensitivity or skin pigmentation (e.g. antibiotics such astetracyclines, antifungals). These medications should be discontinued within 4 weeksof randomization.

16. Known or suspected history of alcohol or drug abuse within 12 months of Screening orin the opinion of the investigator, will interfere with the subject's ability tocomply with the administration schedule and study assessments (alcohol abuse isdefined as regular consumption of >10 standard units of alcohol per week).

17. Subjects who are pregnant or breastfeeding.

18. Clinically significant abnormal laboratory values at Screening:

19. Neutrophils < lower limit of normal.

20. Hemoglobin < 10 g/dL.

21. Platelets < 100 × 109/L.

22. Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 2.0 × upper limitof normal.

23. Estimated creatinine clearance < 30 mL/min or renal disease requiring dialysisas determined by Cockcroft-Gault.

24. Positive serology tests for Hepatitis B surface antigen (HBsAg), hepatitis Cvirus antibody (anti-HCV), or human immunodeficiency virus (HIV)-1 and HIV-2antibody.

25. Subjects who received a live vaccine within 4 weeks prior to Screening.

26. Subjects with known allergy or reaction to any component of the study formulation.